Products for Research Use Only

TPC-144

CAT: 0804-HY-123577Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123577Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TPC-144 is a LSD1/KDM1A inhibitor. TPC-144 inhibits LSD1, and leads to a decrease in the protein level of DNMT1, causing low methylation of the LINE-1 element. TPC-144 can also produce a synergistic effect with Decitabine (a DNMT inhibitor), jointly promoting DNA demethylation and thereby inducing differentiation and apoptosis of leukemia cells. TPC-144 has also demonstrated anti-tumor efficacy in acute myeloid leukemia (AML) models. TPC-144 can be used for the study of AML[1][2].
CAS Number
2098621-17-9
UNSPSC
12352005
Target
Apoptosis; Histone Demethylase
Related Pathways
Apoptosis; Epigenetics
Field of Research
Cancer
Smiles
N[C@H]1C[C@H]2CC[C@@H](C1)N2C(C3=CC(C4=CC=C(C(F)=C4)C#N)=C(C=C3)C5=CC=C(C=C5F)CC(O)(C)C)=O
Molecular Formula
C31H31F2N3O2
Molecular Weight
515.59
References & Citations
[1]Osada A, et al. Abstract A169: Combination of TPC-144, a reversible LSD1 inhibitor, and a hypomethylating agent resulted in synergistic antitumor efficacy in preclinical models of AML. Molecular Cancer Therapeutics. 2018 Jan 1;17 (1_Supplement) :A169-. |[2]Pandey MR, Wang ES. What potential is there for LSD1 inhibitors to reach approval for AML?. Expert opinion on emerging drugs. 2019 Oct 2;24 (4) :205-12.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported